An agricultural technology commercialization company believed that one of its compounds might have human drug use. Anson Pharma experts concurred after reviewing the scientific data then developed and implemented a milestone-paced development plan for advancing the compound through Phase 1 clinical trials.

Anson organized a project team that included a leader with 30 years of pharmaceutical regulatory experience as well as toxicology and clinical research and 5 members with similar depth. The team executed and/or managed all aspects of the program through submission of a successful IND and completion of Phase 1 trials – well within the budgeted time and cost estimates.

When the client continued the project through Phase 2 trials, Anson suggested more aggressive endpoints that would significantly expand the potential market with manageable added risk. The endpoints have been successfully met and the client has completed Phase 3 trials. The NDA has been submitted and is under FDA review.

Anson Group helped this client to add value to its technology by advancing it past critical development milestones and created additional value realization opportunities in a new market.